the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Developmental Therapeutics (Phase I) Cancer Clinical Trials
Interventional only


Study No PI Title
IRB18-0915 Luke, Jason A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Details
IRB18-1038 Kline, Justin An Open label, Phase I/II study to evaluate the safety and efficacy of RP6530, a novel PI3K dual inhibitor given in combination with an anti-PD-1 therapy, Pembrolizumab in adult patients with relapsed or refractory Classical Hodgkin’s lymphoma (cHL) Details
IRB18-0793 Sweis, Randy An open-label, Phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and tumor response profile of the ILDR2 function-blocking antibody BAY 1905254 in patients with advanced solid tumors Details
IRB17-1317 Luke, Jason Platform Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) with Immuno-Oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors Details
IRB17-0375 Catenacci, Daniel An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Advanced Solid Tumor Malignancies Details
IRB17-1038 Luke, Jason A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms Details
IRB17-0762 Luke, Jason A Phase 1 Open-label, Multicenter Study of MK-2118Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB17-0603 Luke, Jason A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas Details
IRB17-0681 Sweis, Randy A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009) Details
IRB16-1071 Luke, Jason A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors Details
IRB15-1561 Luke, Jason A Phase Ia/Ib Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers Details
IRB16-0046 Fleming, Gini Phase I/II Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB15-1807 Luke, Jason A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas Details
IRB15-1130 Chmura, Steven Phase I study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors Details
CIRB15-0606 Polite, Blasé A Multi-Institutional Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Details
IRB14-0704 Gajewski, Thomas A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors Details
IRB14-0862 Fleming, Gini My Pathway - An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents Details
IRB13-0936 Gajewski, Thomas A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors Details
IRB18-0463 Catenacci, Daniel An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine in Patients with Advanced Cancer
10-487-A O'Donnell, Peter The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing Details


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .